AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16209160 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide-containing facial moisturizer applied to the face and one forearm twice daily for 4 weeks
Number of subjects: 50
Study 16209160 — intervention group
Group type: COMPARATOR
Intervention: Untreated forearm (Control)
Number of subjects: 50
Study 16209160 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of facial skin condition by subjects
Number of subjects: 50
Study 16209160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologist evaluation of rosacea condition
Number of subjects: 50
Study 12590721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare bones protocol
Number of subjects: 50
Study 12590721 — intervention group
Group type: COMPARATOR
Intervention: Control method
Number of subjects: 50
Study 9881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiochemotherapy (RCT) + chemotherapy (CT)
Number of subjects: 0
Study 9881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant radiotherapy (RT)
Number of subjects: 0
Study 9881074 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant RT
Number of subjects: 0
Study 9881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative RCT + CT
Number of subjects: 0
Study 9881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative RT
Number of subjects: 0
Study 9881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- or postoperative RCT + CT
Number of subjects: 0
Study 7708069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol chemoembolization (70 mg of cisplatin, 10 ml of lipiodol, and gelatin‐sponge particles delivered through the hepatic artery)
Number of subjects: 96
Study 7708069 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (treatment of complications and pain)
Number of subjects: 96
Study 7708069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol chemoembolization
Number of subjects: 96
Study 2706885 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin lock catheter (n=17)
Number of subjects: 39
Study 2706885 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous line (n=22)
Number of subjects: 39
Study 139565 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (2 or 4 g once)
Number of subjects: 4043
Study 139565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (9 g orally for four days)
Number of subjects: 4043
Study 11436953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 14 weeks
Number of subjects: 11
Study 11436953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 11436953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline group
Number of subjects: 11
Study 30710258 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX‐Sevo (dexmedetomidine-sevoflurane)
Number of subjects: 143
Study 30710258 — intervention group
Group type: COMPARATOR
Intervention: Sevo (sevoflurane)
Number of subjects: 143
Study 29702133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-K+ probiotic formulation (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, Lactobacillus rhamnosus CLR2)
Number of subjects: 0
Study 27037722 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth programme (MASTERY©) supported by a handheld respiratory device and an Android smartphone application (Breathe-easy©) and written asthma action plan
Number of subjects: 72
Study 27037722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 24356624 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Number of subjects: 118
Study 24356624 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg every 3 weeks) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Number of subjects: 118
Study 24356624 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib/paclitaxel/carboplatin
Number of subjects: 118
Study 24356624 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab/paclitaxel/carboplatin
Number of subjects: 118
Study 24356624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 118
Study 22223702 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (MYO) 1200 mg/day for 12 weeks
Number of subjects: 26
Study 22223702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21073267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education programme and care plan (including lifestyle changes, home-based exercise training, weekly nurse consultations)
Number of subjects: 85
Study 21073267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education programme and care plan
Number of subjects: 85
Study 21073267 — intervention group
Group type: COMPARATOR
Intervention: Control group managed according to Russian national guidelines
Number of subjects: 85
Study 17714542 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of sucking and swallowing (one daily session of stimulation according to Vojta)
Number of subjects: 36
Study 17714542 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care (no intervention)
Number of subjects: 36
Study 16918151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple health education program
Number of subjects: 200
Study 16918151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 12107604 — intervention group
Group type: COMPARATOR
Intervention: Leukotriene receptor antagonists
Number of subjects: 52
Study 9657565 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (600 microg b.i.d.)
Number of subjects: 0
Study 9657565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8593200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride (SnF2) dentifrice (SSF)
Number of subjects: 188
Study 2782247 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate (ISMN) 60 mg daily
Number of subjects: 18
Study 2782247 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release isosorbide dinitrate (ISDN) 30 mg, 4 times daily
Number of subjects: 18
Study 2782247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 935199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, 6 doses, given at 6 hour intervals)
Number of subjects: 18
Study 935199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 935199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 31951323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo Ventilation (ASV)
Number of subjects: 1325
Study 31951323 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 1325
Study 31951323 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1325
Study 30889857 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Response Technique (RRT)
Number of subjects: 0
Study 28213743 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 (0.25-45.0 mg/kg)
Number of subjects: 32
Study 28213743 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 (2 mg/kg and above)
Number of subjects: 32
Study 28213743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26531066 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated, multiple, double-dose HB vaccine (40 μg) administered at 0, 1, and 3 weeks before chemotherapy and additional three double doses post chemotherapy.
Number of subjects: 926
Study 26531066 — intervention group
Group type: COMPARATOR
Intervention: Conventional HB vaccine (20 μg) administered at 0, 1, and 6 months.
Number of subjects: 926
Study 23208320 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 100 mg single oral dose
Number of subjects: 8
Study 21947655 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 47
Study 21947655 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study 18465340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 1 year (TAM1)
Number of subjects: 1615
Study 18465340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years (TAM2)
Number of subjects: 1615
Study 18465340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 6 months followed by megestrol acetate for 6 months (TAM/MA)
Number of subjects: 1615
Study 16532442 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (Thermage ThermaCool TC) delivered at 63.5 setting with medium-fast 1.5 cm2 tip over injected sites.
Number of subjects: 5
Study 16532442 — intervention group
Group type: COMPARATOR
Intervention: Control group with augmentation materials alone (no RF treatment).
Number of subjects: 5
Study 12435653 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (N = 33)
Number of subjects: 71
Study 12435653 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (N = 34)
Number of subjects: 71
Study 10332683 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 43
Study 10332683 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 43
Study 7488454 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 20
Study 7488454 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 20
Study 7488454 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 20
Study 2036245 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole (2.5 mg/kg on two consecutive days every week except on chemotherapy days)
Number of subjects: 101
Study 2036245 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study 2036245 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 101
Study 7023596 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 100
Study 7023596 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 100
Study 7023596 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 100
Study 31560220 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometry-based nomogram for predicting metabolic syndrome
Number of subjects: 60799
Study 29564491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon-to-bone repair (87 hips)
Number of subjects: 159
Study 29564491 — intervention group
Group type: COMPARATOR
Intervention: Tendon-to-tendon repair (80 hips)
Number of subjects: 159
Study 29564491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 159
Study 27922626 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 30
Study 27922626 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 30
Study 26966776 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries management strategy 1
Number of subjects: 1124
Study 26966776 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries management strategy 2
Number of subjects: 1124
Study 26966776 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries management strategy 3
Number of subjects: 1124
Study 24012579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive rehabilitation intervention
Number of subjects: 28
Study 24012579 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 21455768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-treated retinopathy of prematurity (n = 7)
Number of subjects: 25
Study 21455768 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously regressed ROP (n = 8)
Number of subjects: 25
Study 21455768 — intervention group
Group type: EXPERIMENTAL
Intervention: No ROP (n = 10)
Number of subjects: 25
Study 21455768 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched full-term children, n = 8)
Number of subjects: 25
Study 18288492 — intervention group
Group type: EXPERIMENTAL
Intervention: K198N coding polymorphism in EDN1
Number of subjects: 0
Study 16221935 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665
Study 16221935 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study 12816220 — intervention group
Group type: EXPERIMENTAL
Intervention: APC tonsillectomy (treatment B)
Number of subjects: 40
Study 12816220 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy (treatment A)
Number of subjects: 40
Study 11191692 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 22
Study 11191692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 22
Study 11191692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9145871 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin capsules (500 mg) administered with food
Number of subjects: 6
Study 9145871 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin capsules (500 mg) administered without food
Number of subjects: 6
Study 7698137 — intervention group
Group type: EXPERIMENTAL
Intervention: k-strophanthidin (0.0035 mg.kg-1 for 10 min)
Number of subjects: 22
Study 7698137 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine (10 micrograms.kg-1.min-1 for 10 min)
Number of subjects: 22
Study 2455126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (20 mg/l in Eurocollin's solution, bolus injection of 0.28 mg/kg, continuous infusion of 0.002 mg/min/kg for 2 days, then 60 mg orally twice daily)
Number of subjects: 63
Study 2455126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (same regimen as Study I without donor pretreatment)
Number of subjects: 63
Study 2455126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 63
Study 2455126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem treatment group
Number of subjects: 63
Study 29699757 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment period
Number of subjects: 139
Study 29699757 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in period (PRI)
Number of subjects: 139
Study 27790252 — intervention group
Group type: COMPARATOR
Intervention: 6% sodium hypochlorite (NaOCl) irrigation (single session treatment)
Number of subjects: 0
Study 27790252 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) mixed with 0.2% chlorhexidine (CHX) as intracanal medicament for two weeks
Number of subjects: 0
Study 25436073 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Sequential Compression Device (ASCD)
Number of subjects: 34
Study 25436073 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous Sequential Compression Device (SSCD)
Number of subjects: 34
Study 23415342 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Evidence-based Medicine course (immediate intervention group, n=58)
Number of subjects: 120
Study 23415342 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (n=62)
Number of subjects: 120
Study 23415342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups throughout the course
Number of subjects: 120
Study 23415342 — intervention group
Group type: EXPERIMENTAL
Intervention: Course evaluation
Number of subjects: 120
Study 23415342 — intervention group
Group type: EXPERIMENTAL
Intervention: Course grading
Number of subjects: 120
Study 23415342 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in further teaching activities
Number of subjects: 120
Study 20100336 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct endomyocardial autologous bone marrow cell injection
Number of subjects: 12
Study 17141245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 276
Study 17141245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 276
Study 17141245 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for pravastatin
Number of subjects: 276
Study 17141245 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for fosinopril
Number of subjects: 276
Study 16368814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg intraoperatively
Number of subjects: 60
Study 16368814 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose remifentanil (Group L: 8 ng/mL)
Number of subjects: 60
Study 16368814 — intervention group
Group type: COMPARATOR
Intervention: Small-dose remifentanil (Group S: 3 ng/mL)
Number of subjects: 60
Study 12076293 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion trigger
Number of subjects: 428
Study 12076293 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of RBC units transfused
Number of subjects: 428
Study 12076293 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion decision
Number of subjects: 428
Study 9805694 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia only
Number of subjects: 52
Study 9805694 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia supplemented by fentanyl (4 micrograms/kg)
Number of subjects: 52
Study 9805694 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia (1% mepivacaine)
Number of subjects: 52
Study 7715291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid (370-400 mg/m2 plus 200 mg/m2 daily for 5 days, every 28 days for 6 cycles)
Number of subjects: 1493
Study 7715291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1493
Study 2707458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) (100 mg) by mouth on cycle days 5 to 9
Number of subjects: 148
Study 2707458 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) (5,000 IU) intramuscularly on cycle days 19, 22, 25, and 28
Number of subjects: 148
Study 2707458 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 148
Study 2707458 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-independent pregnancies (before treatment or more than 1 month after therapy)
Number of subjects: 148
Study 2707458 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF)
Number of subjects: 148
Study 2377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 2377 — intervention group
Group type: COMPARATOR
Intervention: Pantopon
Number of subjects: 0
Study 7343127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (chemoprophylaxis) given every 15 days
Number of subjects: 100
Study 7343127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31774411 — intervention group
Group type: EXPERIMENTAL
Intervention: Run4Love mHealth intervention
Number of subjects: 300
Study 28104830 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy (HFOT)
Number of subjects: 14
Study 28104830 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 14
Study 28104830 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study 27931242 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL intervention (goal-setting intervention)
Number of subjects: 48
Study 27931242 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 48
Study 24434951 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigmatizing video
Number of subjects: 123
Study 24434951 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 123
Study 22996350 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heating (HT)
Number of subjects: 10
Study 22996350 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 22996350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (CL)
Number of subjects: 10
Study 18987560 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital spastic hemiplegia group
Number of subjects: 0
Study 18987560 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 0
Study 17300543 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management program (10 sessions)
Number of subjects: 18
Study 17300543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 14693596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg/kg
Number of subjects: 0
Study 14693596 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.60 mg/kg
Number of subjects: 0
Study 11981422 — intervention group
Group type: EXPERIMENTAL
Intervention: XM-positive BSCT
Number of subjects: 60
Study 11981422 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for disease, disease stage, patient age, period of transplant, conditioning regimen, protocol for prevention of graft-versus-host disease, type of donor)
Number of subjects: 60
Study 9618627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise classes
Number of subjects: 99
Study 9618627 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education classes
Number of subjects: 99
Study 7714113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during euglycemic conditions
Number of subjects: 2
Study 7714113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during hyperglycemic conditions
Number of subjects: 2
Study 7714113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 2
Study 7714113 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion during hyperglycemic vs euglycemic conditions
Number of subjects: 2
Study 2695820 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyloxymethyl-thiamin
Number of subjects: 100
Study 2695820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 926982 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarine
Number of subjects: 36
Study 926982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31478708 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity trackers with online coach
Number of subjects: 116